The Alzheimer’s Disease Cooperative Study (ADCS), in collaboration with the National Institute on Aging and the Alzheimer’s Association, is developing a nationwide information network of people who wish to receive information about Alzheimer’s disease research and learn about upcoming clinical research studies.
Who Can Benefit?
Members of the confidential Alzheimer’s Disease Information Network (AD-IN) may, for example:
• Have a diagnosis of probable AD
• Have a family member with probable AD
• Have an undiagnosed memory problem/disorder or know someone who does.
• Have an interest in learning about AD and dementia.
• Wish to participate in a current or future ADCS clinical trial.
About the ADCS and What It Does
The ADCS was instituted by the National Institute on Aging and University of California, San Diego. Currently it includes a collaboration of 79 top research centers in the U.S. and Canada. The goal: “To advance research in the development of drugs that might be useful for treating patients with Alzheimer's disease, particularly drugs that might not be developed by industry… This includes the testing of agents that:
• Lack patent protection,
• Are under patent protection but are already marketed for other indications but where the agent may be useful in treating AD, and
• Are novel compounds developed by individuals, academic institutions and drug discovery units.”
Studies Currently Open for Enrollment include for example:
• RI (RAGE Inhibitor) – Reducing Amyloid in Alzheimer’s Disease – 4-year study that will involve 399 volunteers with mild to moderate Alzheimer’s at 40 sites.
• Home-Based Assessment Study – recruiting 600 volunteers nationwide age 75 and older, presently with normal memory.
The 79 Research Centers:
To review the US and Canadian research centers participating in the ADCS collaborative, see the List of ADCS Clinical Sites. Most listings include a live link to information about the center’s Alzheimer’s program, experts, and activities.